✦ LIBER ✦

Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia

✍ Scribed by Alessandro Gozzetti; Pellegrino Musto; Marzia Defina; Fiorella D'Auria; Giulia Papini; Teodora Steduto; Giovanni D'Arena; Monica Bocchia

Book ID: 114714620
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 72 KB
Volume: 157
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2012.09029.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lenalidomide (Revlimid), bortezomib (Vel

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia

✍ Jimenez-Zepeda, Victor H.; Reece, Donna E.; Trudel, Suzanne; Chen, Christine; Ti 📂 Article 📅 2014 🏛 Informa plc 🌐 English ⚖ 142 KB

Lenalidomide cutaneous adverse event: a

Lenalidomide cutaneous adverse event: a case of Stevens–Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone

✍ A. Siniscalchi, A. Tendas, L. Morino, T. Dentamaro, A. De Bellis, A. Perrotti, P 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 121 KB

Efficacy and safety of bortezomib in pat

Efficacy and safety of bortezomib in patients with plasma cell leukemia

✍ Pellegrino Musto; Fausto Rossini; Francesca Gay; Vincenzo Pitini; Tommasina Gugl 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 1 views

## Abstract ## BACKGROUND. The prognosis of patients with plasma cell leukemia (PCL), an aggressive variant of multiple myeloma (MM), is usually poor. Bortezomib is the first proteasome inhibitor approved for the treatment of advanced MM. Currently available information regarding the role of borte

68 POSTER Sensitivity of a disseminated

68 POSTER Sensitivity of a disseminated in vivo model of L363 plasma cell leukaemia against antitumoral compounds sorafenib, bortezomib, and dexamethasone

✍ J. Schueler; D. Wider; M. Wagner; H.H. Fiebig; M. Engelhardt 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 56 KB